- Full Title: Al based on evolutionary computation yields algorithmic biomarker
- summary of a randomized rheumatoid arthritis clinical trial, accurately predicting
- individual patient outcomes, enabling precision medicine.
- Short Title: Algorithmic clinical trial summary predicting individual patient outcomes.
- Kevin Horgan^{1*}, Michael F. McDermott², Douglas Harrington³, Vahan Simonyan⁴,
- Patrick Lillev^{1,5}
- ¹ Liquid Biosciences, 6B Liberty, Suite 228, Aliso Viejo, CA 92656
- ²Leeds Institute of Rheumatic and Musculoskeletal Medicine. University of Leeds.
- LS9 7TF, Leeds, UK.
- ³ Montana Department of Health and Human Services, Helena, MT 59601
- ⁴ Department of Biochemistry and Molecular Medicine, George Washington School
- of Medicine and Health Sciences, Washington, D.C. 20052
- ⁵ Ignite Biomedical, Medfield, MA 02052
- *kevinh@liquidbiosciences.com

ADDITE Partitions ports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 35 ACR American College of Rheumatology
- 36 CDAI clinical disease activity index
- 37 CRP C-reactive protein
- 38 DAS28 disease activity score 28
- 39 DLDA diagonal linear discriminant analysis
- 40 DMARD disease modifying anti-rheumatic drugs
- 41 DQDA diagonal quadratic discriminant analysis
- 42 EC: evolutionary computation
- 43 EULAR European League Against Rheumatism
- 44 GEO gene expression omnibus;
- 45 LOO leave one out
- 46 LDA -linear discriminant analysis
- 47 MTX methotrexate
- 48 OLS orthogonal least squares
- 49 RA rheumatoid arthritis
- 50 RF random forest
- 51 SVM support vector machine
- 52 TNF tumor necrosis factor
- 53 UHC unsupervised hierarchical clustering

- 55
- 56

57 Abstract

Background: Producing transparent interpretable algorithms summarizing clinical
trial outcomes to accurately predict individual patient's responses would be a
significant advance. We hypothesized that software designed to analyze biomedical
data, based on evolutionary computation (EC), could produce summary algorithmic
biomarkers from a clinical trial, predictive of individual responses to therapy.

Methods and Findings: A previously published randomized double-blind placebo 63 controlled clinical trial was analyzed. Patients with active rheumatoid arthritis on a 64 65 stable dose of methotrexate and naive to anti-tumor necrosis factor biologic therapy. were randomized to receive infliximab or placebo. The primary endpoint was 66 67 synovial disease activity assessed by magnetic resonance imaging. Secondary endpoints included the Disease Activity Score 28 (DAS28). Baseline peripheral 68 blood gene expression variable data were available for 59 patients, plus the 69 treatment variable, infliximab or placebo, yielding a total of 52,379 baseline 70 71 variables. The binary dependent variable for analysis was DAS28 response, defined by a decrease in DAS28 score of ≥1.2, at 14 weeks. At 14 weeks, 20 of the 30 72 patients receiving infliximab had responded, and ten of the 29 patients receiving 73 placebo had responded. The software derived an algorithm, with 4 gene expression 74 variables plus treatment assignment and 12 mathematical operations, that correctly 75 76 predicted responders versus non-responders for all 59 patients with available gene expression data, giving 100% accuracy, 100% sensitivity and 100% specificity. We 77 present the algorithm to provide transparency and to enable verification. Excluding 78 the 4 gene expression variables, we then derived similarly predictive algorithms with 79 4 other gene expression variables. We hypothesized that the software could derive 80

algorithms as predictors of treatment response to anti-tumor necrosis factor biologic 81 therapy using just these 8 gene expression variables using previously published 82 independent datasets from 6 rheumatoid arthritis studies. In each validation analysis 83 the accuracy of the predictors we derived surpassed those previously reported by 84 the original study authors. 85 **Conclusions and Relevance:** Software based on EC summarized the outcome of a 86 clinical trial, with transparent biomarker algorithms correctly predicted the clinical 87 outcome for all 59 RA patients. The biomarker variables were validated in 6 88 independent RA cohorts. This approach simplifies and expedites the development of 89 90 algorithmic biomarkers accurately predicting individual treatment response, thereby

91 enabling the deployment of precision medicine, and, in the future, providing a basis

92 for dynamic labeling of prescription drugs. Original Trial Registration used for

93 analysis: ClinicalTrials.gov registration: NCT01313520

94

96 Introduction

Randomized clinical trial outcomes are conventionally analyzed using a prespecified 97 98 hypothesis and statistical tests based on the average overall response in order to assess whether treatment is effective at a population level. Much information in the 99 clinical trial data is neglected with this approach resulting in a lack of guidance for 100 clinicians and patients as to which individuals might benefit from the therapy. This is 101 reflected in product labels that are devoid of individual guidance. An analytic 102 methodology is needed that incorporates all the available trial data to yield predictors 103 of therapeutic outcomes in individual patients. 104

An algorithm is a formula for processing and summarizing information enabling 105 predictions and understanding of the underlying mechanisms. An analytic approach 106 107 that utilizes all information from a clinical trial, and mathematically derives an objective transparent interpretable digital algorithmic biomarker set predicting 108 109 individual response would be a significant advance. Individual treatment 110 recommendations could then be based on a quantitative objective predictive model, 111 easily validated, fulfilling the goal of precision medicine by enabling the right patient to receive the right therapy. The aspiration that machine learning AI would enable 112 this transformative vision to be fulfilled has not yet been realized, hindered by lack of 113 transparency [1, 2]. Living organisms are complex systems [3]. Biological functions, 114 such as disease and drug responsiveness, result from complex networks of cellular 115 and molecular interactions that can potentially be described mathematically reflecting 116 mechanisms and constraints under which biological systems operate [3-6]. These 117 interactions are typically nonlinear and multi-dimensional which complicates 118 analyses. 119

We developed software based on EC, incorporating a comprehensive set of
mathematical functions, to produce transparent interpretable algorithms from
complex biomedical data, specifically designed to address nonlinearity and high
dimensionality typical of complex emergent systems. The algorithms produced are
verifiably accurate mathematical solutions to the outcome of interest.

The objective was to apply the software to a published placebo-controlled clinical 125 trial of infliximab in rheumatoid arthritis (RA), conducted by a pharmaceutical 126 127 company with baseline peripheral blood transcriptomic data [7,8]. Infliximab is a monoclonal anti-tumor necrosis factor (TNF) alpha antibody effective in treating a 128 129 range of immune mediated disease including RA. The hypothesis was that the software would produce transparent, interpretable, algorithms predictive of treatment 130 response that could be independently validated. We selected this trial because it 131 was randomized, and placebo controlled with tens of thousands of data points 132 available for each patient to provide a rigorous test. The software produced an 133 algorithm comprised of biomarker measurements, clinical variables, and 134 mathematical functions, highly predictive of infliximab treatment outcome containing 135 just four gene expression variables and treatment assignment. When we excluded 136 those four gene expression variables in the original algorithm from subsequent 137 analyses, we were able to derive additional algorithms, with four additional gene 138 expression variables, with similar predictivity. 139

Having identified the eight gene expression variables, we then hypothesized that applying the software using only those eight variables, to previously published data from six additional RA studies containing baseline gene expression data would derive predictors of clinical outcomes following anti-TNF treatment. In each case,

using these eight gene expression variables, the software provided an algorithm
more predictive of treatment response than reported in the original publications,
thereby independently validating both the gene expression variables as response
predictors, and our methodologic approach.

148 Methods

149 **Discovery Cohort**

150 The discovery cohort was from a published, four European center, randomized,

double-blind placebo-controlled trial of infliximab, in RA patients naïve to biologic

therapy following an inadequate response to methotrexate [7,8]. Active disease was

defined as at least 6 tender and 6 swollen joints, with a rheumatoid arthritis magnetic

resonance imaging score of ≥ 1 in the radio-carpal or intercarpal joints, as objective

155 confirmation of disease activity. The patients were all on stable doses of

methotrexate, steroids, and/or non-steroidal anti-inflammatory drugs. At weeks 0, 2,

157 6, and 14, the participants received either infliximab 3 mg/kg or placebo. The

patients were of mean age of 50 years, predominantly female (92%), and

rheumatoid factor positive (91.5%), with a mean baseline DAS28 score of 6.2. The

primary endpoint was a magnetic resonance imaging assessment of disease activity.

161 This endpoint was not used in our analysis, because the imaging data were not

available for individual patients. The trial used the European League against

163 Rheumatism (EULAR) DAS28 score to evaluate response, defined as a decrease of

 ≥ 1.2 , as a binary dependent variable for the analysis at 14 weeks, yes or no.

165 Baseline peripheral blood gene expression data for 59 patients were available plus

an additional variable reflecting treatment, either infliximab or placebo, resulting in a

total of 52,379 potentially independent variables.

168 Validation Cohorts

- 169 To independently validate the gene expression variables in the discovery algorithms,
- we applied these variables to 6 previously published studies with available baseline
- gene expression data from patients with active RA, treated with anti-TNF therapies
- 172 [9-14]. These studies were done in different geographies, used different
- 173 methodologies to process the samples and gene expression data, had different
- endpoints, and in some cases, used different anti-TNF therapies [9-14]. Summary
- details on the discovery and validation studies are provided in Table 1, with details
- available in the original publications [9-14].

Table 1 – Discovery and validation studies of blood-based gene expression data of anti-TNF responsiveness in RA

Eirot	Maalaaaa at	Loguarro at	lulia at al	Dionkowaka	Toopop of	Nakamura	Tanina at
FIISL				Dielikowska		Nakamura	ranno et
author	al (2014) ^{7,0}	al (2005) ⁹	(2009)10	et al	al (2011) ¹²	et al	al
				(2009)11		(2016) ¹³	(2010)14
GEO	GSE58795	GSE5392	GSE12051	GSE15258	GSE33377	GSE78068	GSE20690
accession							
	Discovery	Validation	Validation	Validation	Validation	Validation	Validation
Location	Moldova & Bomania	France	Spain	USA	Netherlands	Japan	Japan
BA	BAACB	BA ACB	BAACB	BA	BAACB	BA ACB	Not
diagnostic	(1987)	(1987)	(1987)		(1987)	(1987) or	reported
criteria	(1007)	(1007)	(1007)		(1007)	FULAB/ACB	roponou
ontonia						(2010)	
Treatment	infliximab or	infliximab	infliximab	infliximab	infliximab	infliximab	infliximab
	placebo			adalimumab	and		
	piacoso			etanercept	adalimumab		
RA	MTX resistant.	МТХ	МТХ	Active RA:	DMARD	MTX resistant	мтх
treatment	No prior TNF	resistant.	resistant.	No TNF in	resistant.		resistant
population	therapy	DAS28>=5.1	DAS28>3.2.	past 6	DAS28>3.2.		
P - P			No prior	months	No prior		
			TNF therapy		TNF therapy		
Platform	Rosetta/Merck	Affvmetrix	Illumina H-6	Affvmetrix	Affymetrix	Agilent-	Agilent-
	custom	Human	mRNA	Human	GeneChip	014850	014850
	Affymetrix 2.0	Genome	Sentrix	Genome	Exon 1.0 ST	Whole	Whole
	microarray	U133A Array	Human-6	U133 Plus		Human	Human
	,	,	Expression	2.0 Array		Genome	Genome
			BeadChip			Microarray	Microarrav
						4x44K	4x44K
						G4112F	G4112F
Efficacy	14-week	14-week	14-week		14-week	6-month	14-week
	EULAR	EULAR	EULAR		EULAR	CDAI	serum
	criteria	criteria	criteria		Criteria		CRP

179

180 GEO – gene expression omnibus; RA – rheumatoid arthritis; ACR – American College of Rheumatology; MTX –

181 methotrexate; EULAR – European League Against Rheumatism; DAS28 – disease activity score 28; TNF –

182 tumor necrosis factor; DMARD – disease modifying anti-rheumatic drugs; CRP – C-reactive protein; CDAI –

183 clinical disease activity index.

184 Microarray data

- 185 The gene expression profiles analyzed were downloaded from the GEO database.
- 186 Because all the data used were de-identified and publicly available, neither ethics
- 187 committee approval nor informed consent were required.
- Datasets were downloaded and transposed so that gene expression values and clinical variables were changed from rows to columns, and subject records were changed from columns to rows. Data files were saved in CSV format and imported into the software for analysis, without any processing.
- 192

193 Analysis

The software is a quantitative artificial intelligence platform based on EC, designed 194 as a scalable, unbiased methodology to produce transparent algorithms based on 195 mathematical relationships from complex data, without any prior assumptions other 196 197 than the patient selection criteria used in the studies yielding data for analysis. The software fuses evolutionary principles, signal processing functions, and information 198 theory, and requires no domain expertise or prior knowledge of the nature of a 199 problem in terms of explanatory variables, dimensionality or underlying mathematical 200 relationships. A distinctive feature is that the software uses all available data to 201 derive the algorithms, without any filtering process to exclude variables based on 202 commonly used thresholds or feature selection methods. This enables the 203 identification of variables typically discarded by feature selection methods used in 204 biomarker discovery with relatively low expression or non-linear relationships to the 205 206 outcome, but which may be functionally important because of the non-linear and

207	binary threshold interactions pervasive in complex biologic systems. The software
208	identifies both key variables and their mathematical relationships, associated with
209	outcomes of interest. The software automatically divides the data into three distinct,
210	random subsets that are sequentially processed: a training set, a selection set, and a
211	test set. Analysis of the training subset provides an ensemble of candidate
212	algorithms, which are then evaluated on the selection subset, to select a final
213	algorithm, which is then validated on the test set. The training, selection, and test
214	data subsets are scrupulously segregated, to avoid any information leakage between
215	the discrete components of the process. In the discovery analysis of the MacIsaac et
216	al. data, there were 20 patients in the training set, 20 in the selection set and 19 in
217	the test set (Table 2).

	Analysis of data from MacIsaac et
	al.[7]
Training set	
Errors/total	0/20
Accuracy	100%
Misclassification rate	0%
Validation set	
Errors/total	0/20
Accuracy	100%
Misclassification rate	0%
Test set	
Errors/total	0/19
Accuracy	100%
Misclassification	0%
Overall Accuracy	100%
Overall Sensitivity	100%
Overall Specificity	100%
Number of gene expression variables	4

218 Table 2 Discovery Algorithm Metrics

- The 8 variables in the discovery algorithms were then applied to the analyses of six
- additional published data sets in patients with RA, using both baseline gene

- 222 expression data and response outcomes to anti-TNF therapy, for independent
- validation.
- 224 Findings
- 225 Discovery Analysis: Derivation of MacIsaac et al Algorithm
- The software initially yielded an algorithmic biomarker set with five variables and
- twelve sequential mathematical instructions as shown in Table 3. The Gene
- expression variables expressed quantitatively: SPTY2D1, Clorf105, KCTD4 and
- 229 UL84 and treatment assignment: infliximab or placebo.

230 Table 3 Discovery Algorithm as Series of Operations

231

	Input	
Instruction	Registers	Explanation
r[03] = SINCPI(r[03])	r[03] = 19	Calculate the sine of 19, divide that by 19 and push the result (0.00788827419278696) into memory register 03
r[06] = SUB(r[13], r[02])	r[13] = KCTD4, r[02] = 7	Subtract 7 from the measurement of RNA KCTD4, then push the result into register 06
r[04] = ADD(r[15], r[01])	r[15] = Treatment_num, r[01] = 2	Add Treatment_num to 2 and push the result into register 04. Treatment_num 0 is placebo, Treatment_num 1 is infliximab.
r[05] = ADD(r[10], r[06])	r[10] = SPTY2D1	Add the value in register 06 to the measurement of RNA SPTY2D1 and push the result into register 05
r[01] = DIV(r[02], r[04])	r[02]= 7	Divide 7 by the value in register 04 and push the result into register 01
r[00] = SINCPI(r[09])	r[09] = UL84	Calculate the sine of the measurement of RNA UL84, divide that by the measurement of RNA UL84, and push the result into register 00
IF(r[00] < r[03])		If the value in register 00 is less than the value in register 03, then execute the following instruction, otherwise skip it
IF(r[11] < r[01])	r[11] = C1orf105	If the measurement of RNA C1orf105 is less than the value in register 01, then execute the following instruction, otherwise skip it
r[00] = ADD(r[04], r[05])		If both of the above IF statements are TRUE, then add the value in register 04 to the value in register 05 and push the result into register 00. If one or both of the above IF statements are false, skip this instruction.
r[05] = DIV(r[11], r[00])	r[11] = C1orf105	Divide the measurement of RNA C1orf105 by the value in register 00, and push the result into register 05
r[04] = CONSTDIV(7, 5)		Divide 7 by 5 and push the result into register 04
r[00] = ADD(r[04], r[05])		Add the value in register 04 to the value in register 05, and push the result into register 00
Final interpretation		If the contents of memory register 00 are negative, then patient is predicted to be a non-responder, otherwise a responder

232

The algorithm is presented in the form of an equation here.



235

- To facilitate validation the algorithm is also shown as a schematic in Fig 1.
- A calculation for an individual patient, with a resulting value of less than zero
- indicated treatment non-response, and a value of zero or more indicated treatment
- response. The baseline values for the four gene expression markers, for each of the
- 59 patients, are present in S1 data`to enable verification of the algorithm.

241 Fig 1 Legend: Discovery Algorithm in Schematic Form

242

- 243 The variables were treatment assignment (placebo versus infliximab therapy) and
- four gene expression variables: SPTY2D1, C1orf105, KCTD4 and UL84 (Table 4).

245 Table 4 Gene Expression Variables

E	pression Variable	Function
SPTY2D1	suppressor of Ty 5 homolog	tumor suppressor gene in thyroid cancer [15]
C1orf105	chromosome 1 open reading frame	vascular remodeling, coronary artery disease and atrial fibrillation [16,17]
KCTD4	potassium channel tetramerization domain containing 4	expressed in sepsis and esophageal cancer [18, 19]
UL84	gene for human CMV protein UL84	prior CMV infection associated with treatment response in RA [20,21]
PTPRC	Protein Tyrosine Phosphatase Receptor Type C or CD45	genetic variants associated with anti-TNF response in RA [22,23]
TPM3	Tropomyosin 3	tropomyosin isoform associated with neoplasia, myopathy and as an autoantigen in RA [24-26]
ARHGDIB	Rho GDP Dissociation Inhibitor Beta	negative regulator of Rho guanosine triphosphate (RhoGTP)ases, reduced in osteoarthritis synovial fluid and elevated in early RA synovial fluid [27,28]
SIAH1	Siah E3 Ubiquitin Protein Ligase 1	downregulated in both RA and tuberculosis, may influence amplitude of inflammatory gene response [29]

These variables were not those with the highest levels of expression. Agnostic evolutionary selection of treatment as a variable, either infliximab or placebo, into the predictive algorithm is evidence that the treatment has a mathematically significant impact on the response outcome for some patients. Although expected a priori, the treatment assignment variable was selected agnostically by the evolutionary process, and not pre-specified. Users of the software cannot influence or require any variable to be incorporated into an algorithm.

254 The performance metrics for the components of the discovery analyses are shown in Table 2, with 20 patients in the training set, 20 in the selection set and 19 in the test 255 256 set. The overall accuracy was 100% with 100% sensitivity and specificity. Repeat analyses consistently yielded exactly the same variables, and the mathematical 257 instructions encoded in all algorithms were, without exception, mathematically 258 equivalent in terms of binary outcome: response or non-response. Omission of any 259 of the mathematical instructions from the algorithm degraded predictivity. Therefore, 260 the algorithm was optimized and devoid of superfluous calculations. Accuracy and 261 reliability were consistent across training, validation and test sets analysed. When 262 the initial four gene expression variables were excluded from subsequent analyses. 263 four additional gene expression variables were identified as components of 264 algorithms also with 100% accuracy: PTPRC, TPM3, ARHGDIB and SIAH1 (Table 265 4). The software selects the minimum number of variables for maximum accuracy. 266 267 The fact that a second group of four variables provided algorithms with 100% accuracy implies that these variables are highly correlated with the original four, 268 containing almost as much information. The x-y plots of the 8 individual markers 269 versus DAS28 change are nonlinear: see S1 data. 270

271 Validation of gene expression variables by analysis of six independent

272 datasets

- 273 We then tested the hypothesis that the eight variables from the discovery algorithms
- 274 could be used to derive algorithms predicting individual treatment response
- outcomes from six additional published data sets, providing independent validation.
- 9-14). While the eights variables used were the same for all six dataset analyses,
- 277 distinct algorithmic operations were necessary for each validation because of
- variation in quantitation instruments, measurement scale, data preparation and
- 279 normalization methods across the individual datasets. Demographic details are
- shown in Table 1. In each case, the algorithms we produced had superior
- performance to the analyses presented in the original publications as shown in Table
- 5, even though only a subset of the eight discovery variables were available in some
- datasets. Table 5 shows the metrics for predictors presented in the original
- 284 publications for each study, and also the metrics for the consistently superior
- algorithmic predictors we derived using the data from each study.

Table 5 – Discovery and validation studies of blood-based gene expression data of anti-TNF responsiveness in RA

First author	MacIsaac [7]	Lequerre [9]	Julia [10]	Bienkowska [11]	Toonen [12]	Nakamura [13]	Tanino [14]
Number of patients	59	30	44	46 – leaving out intermediate responses or 75 including intermediate responses	42	140 (infliximab treated)	68
Classifier Method	OLS regression	UHC	SVM, DDA, RF, & k-NN	RF	K-means cluster analysis	Logistic regression	LOO
Cross- validation analyses	None	LOO	LOO	LOO, NN, LDA and SVM	None	None	None
Original reported results	None reported	Sens 90% Spec 70%	Sens 94% Spec 86%	Sens 88% Spec 84%	Sens 61% Spec 71%	Sens 79% Spec 47%	Sens 68% Spec 86%

It is made available under a CC-BY 4.0 International license .	
--	--

Current analysis	Sens 97% Spec 100%	Sens 100% Spec 100%	Sens 100% Spec 86%	Sens 100% Spec 86%	Sens 100% Spec 96%	Sens 95% Spec 91%	Sens 96% Spec
			•				84%

288

UHC – unsupervised hierarchical clustering; OLS – orthogonal least squares; LOO – leave one out; LDA - linear
 discriminant analysis; SVM – support vector machine; RF – random forest; DLDA – Diagonal Linear Discriminant
 Analysis; DQDA – Diagonal Quadratic Discriminant Analysis.

- 292 The weighted-average sensitivity and specificity of the individual models from the
- analyses we conducted across all 7 datasets, with a total of 400 subjects treated
- with anti-TNF therapy, was 98.5% and 90.9%, respectively surpassing the accuracy
- of all the prior published individual analyses, as shown in Fig 2. The biomarker
- variables held up across 7 patient datasets, 3 different TNF inhibitor drugs, 3
- 297 continents, multiple ethnicities, despite differences in response criteria, RNA
- 298 expression and processing platforms and measurement scale differences.

Fig 2 Discovery and validation studies of blood-based gene expression data of anti-TNF responsiveness in RA

Weighted-average accuracy of individual analyses of 7 datasets, on all 400 subjects receiving anti-TNF therapy [7-14]. 98.5% sensitivity and 90.9% specificity surpassed all individual previously reported analyses, as did our 84.5% positive predictive value, and 99.2% negative predictive value. Accuracy for the marketed TNF predictor from two reports, Jones et al and Mellors et al, is also presented for comparison [30,31].

307

308 Discussion

309 We have shown that an EC based analytic approach incorporating mathematical

- 310 functions derives transparent interpretable biomarker algorithms highly predictive of
- individual patient responses from clinical trials. The algorithms and their high
- 312 predictivity are notable, since none of the predictive biomarkers we identified were
- identified in the original clinical trial publication used for discovery [8]. In each of the
- six validation analyses, the derived algorithms had sensitivity and specificity superior
- to those in the original publications, which used a variety of mainstream analytic

approaches: see Fig 2. None of the publications associated with the six validation 316 datasets reported clinical utility of the eight predictive biomarkers identified in our 317 analyses. Context for comparatively assessing the approach we used is provided by 318 an existing marketed predictive test, derived using machine learning, for TNF 319 response. This predictive test identified non-responders with a specificity of 86.8 and 320 sensitivity of 50.0% in one report by Mellors et al and specificity of 77.3% and 321 sensitivity of 60.2% in another study by Jones et al [30.31]. The predictive test 322 contains 23 variables: 19 gene expression variables, plus anti-cyclic citrullinated 323 protein serostatus, sex, body mass index, and a patient global assessment [30]. 324 325 None of the gene expression variables in this RA predictor overlap with the 8 variables we identified. In contrast, the weighted average of our RA treatment 326 327 response predictor has a sensitivity of 98.5% and specificity of 90.4%, although this 328 is not a direct comparison using the same datasets. The underlying data used to 329 derive the marketed predictive test and its algorithm were not available to analyze for a direct comparison with our analyses of the seven datasets we used for discovery 330 331 and validation.

The use of this form of EC to derive an explanatory and predictive algorithm 332 summarizing a clinical trial outcome is novel. EC has been claimed to have 333 significant advantages leading to its description as a major transition in AI [32]. EC 334 uses core concepts from evolutionary biology - inheritance, random variation, and 335 336 selection - to derive algorithms from data which may make it particularly suitable for analysis of biomedical data [32]. This form of EC leverages the strengths of EC in 337 general and does not depend on prior assumptions, provides highly interpretable 338 algorithms, and can provide solutions from modest sample sizes [32]. In addition, the 339

EC approach is entirely agnostic, and does not use any arbitrary thresholds to eliminate variables from consideration. These various advantages are confirmed by our findings, and contrast with inflexible analytic methods, that may create the erroneous impression of greater noise and randomness than is <u>actually</u> present in the observed data. We presented an example of an algorithm to enable conclusive confirmation of its validity and <u>provide easy access</u> to the data used for its derivation in the supplementary material.

347

The eight specific gene expression variables in our predictive algorithms may 348 349 provide insights into the molecular mechanisms underlying responsiveness to anti-TNF therapy in RA. The eight variables were not individually highly correlated with 350 351 response, likely reflecting the importance of nonlinear interactions in biology, 352 modelled by the mathematical components of the algorithms. There are no prior 353 reports directly linking SPTY2D1, KCTD4, and c1orf105 to either RA, immunemediated diseases or to responses to therapy. Prior cytomegalovirus (CMV) 354 355 exposure has been associated with poor responses to therapy in early RA [20,21,31] which may explain the UL84 gene variable as it encodes for a CMV protein, 356 357 essential for viral replication. Mutations in PTPRC, also known as CD45, have been associated with RA patient response to anti-TNF therapy [22,23]. TPM3 has been 358 reported as an autoantigen in in RA, and also to involved in myopathy and renal 359 cancer [24,25,26]. ARHGDIB expression has been reported to be upregulated in RA, 360 whereas SIAH1 is downregulated [28,29]. TPM3, ARHGDIB and SIAH1 have not 361 been associated with therapeutic outcomes. 362

363

Medical information is accumulating at an accelerating pace, creating challenges for 364 clinicians to process, discuss with patients and implement objective data driven 365 therapeutic recommendations [33.34]. The notion that the future of medicine will 366 ultimately be based on computer derived algorithms is not recent or novel [33-35]. 367 More than 50 years ago, William Schwartz predicted that computing would be 368 augmenting and, in some cases, even replacing the intellectual functions of 369 physicians [35]. The practice of medicine has been "algorithmic" even before the 370 introduction of computers to medicine and the digitization of medical information [36]. 371 Diagnostic and therapeutic clinical guidelines, often described as algorithms, for 372 373 many prototypical clinical syndromes, and codified by experts, have been integral to the practice of medicine for decades [36,37]). As Margolis wrote in 1983, clinical 374 375 "algorithms are needed primarily to define the practice of rational medicine" [36]. The progression to a more prominent role of software-derived algorithms in medicine is 376 377 inevitable, given the current explosion of data [34,35,38,39).

A novel analytic approach that reflects the entirety of the trial data to inform 378 individual treatment decisions, in accordance with the aspirations of precision 379 medicine is desirable, especially now that clinical trials are frequently collecting 380 digital and multi-omic data sets. The relatively simple, objective, transparent, 381 interpretable algorithms we report, the ease of their independent validation that we 382 have illustrated, and their superior performance are compelling advantages. In 383 384 contrast, the cryptic, opaque, black box products that typical AI machine learning yields are not desirable for informing medical decisions [2,40]. 385

The novel approach we report and the noteworthy findings we present all warrant rigorous evaluation because of their potential ramifications. The biomarker variables

were discovered in a clinical study conducted in Romania and Moldova and were 388 validated in 6 other independently conducted studies with different TNF inhibitors, on 389 3 continents, in multiple ethnicities, despite differences in response criteria, RNA 390 expression and processing platforms and measurement scale differences, thereby 391 providing extremely high confidence as to their validity. The software analysis is 392 objective because no assumptions are made in order to influence its identification of 393 the optimal variables or mathematical operations. Any potential bias would be a 394 consequence of selection criteria and study designs of the original clinical studies 395 that yielded the gene expression data. Our consistent findings across all the 396 397 independent datasets argue strongly against any bias compromising the validity of the predictor variables. While the eight biomarkers are appropriate for clinical use, 398 399 the discovery-stage gene expression instruments used to derive the datasets have 400 different quantitation levels and reliability than clinical-grade assay processes and 401 technology. Therefore, a diagnostic test is undergoing development for clinical use, incorporating the eight identified variables using clinical grade assay processes and 402 403 technologies. A novel algorithm will then be derived and rigorously validated for the developed test to ensure optimal performance and clinical utility. 404

405 The algorithmic biomarkers we report can be updated and validated as new multi-

406 faceted data become available, continually refining their accuracy and

407 generalizability, and amplifying confidence in their utility. Such algorithms could be

incorporated into dynamic product labels to ensure that individual treatment

409 decisions optimally reflect the available data.

410 Conclusion

411	The provision of transparent highly predictive algorithmic biomarkers, with user
412	friendly tools for deployment avoiding onerous calculations, will reduce the cognitive
413	burden of physicians and help improve the quality of their consultations.
414	Emancipating clinicians to rationally practice the art of medicine, on a quantitative,
415	scientific foundation, informed by validated interpretable algorithms, derived by EC
416	based quantitative AI, could accelerate the implementation of precision medicine,
417	and enhance the quality of health care.
418	
419	
420	
421	
422	
423	
424	
425	
426	Acknowledgements: Richard Gallagher, Mary Beth Yacvshyn, Tony Ho, David
427	Madigan and Poul Strange provided useful comments on early versions of the
428	manuscript.
429	Author Contributions
430 431	Conceptualization: Kevin Horgan. Michael F. McDermott. Douglas Harrington.
432	Vahan Simonyan, Patrick Lilley.
433 424	Data curation project administration and software: Patrick Lillow
434 435	Data curation, project administration and software. Fattick Liney

- **Methodology:** Kevin Horgan, Vahan Simonyan, Patrick Lilley.
- Interpretation: Kevin Horgan, Michael F. McDermott, Douglas Harrington, Vahan
 Simonyan, Patrick Lilley.
- **Formal analysis:** Patrick Lilley.

- **Visualization:** Vahan Simonyan, Patrick Lilley.
- 445 Writing original draft: Kevin Horgan, Michael F. McDermott, Patrick Lilley.
- Writing review and editing: Kevin Horgan, Michael F. McDermott, Douglas
 Harrington, Vahan Simonyan, Patrick Lilley.

453 **References**

- Wilkinson J, Arnold KF, Murray EJ, van Smeden M, Carr K, Sippy R et al. Time
 to reality check the promises of machine learning-powered precision medicine.
 Lancet Digit Health. 2020;12:e677-e680. PMID: 33328030.
- 457 2. Price WN. Big data and black-box medical algorithms. Sci Transl Med.
 458 2018;10:471. PMID: 30541791
- 459 3. Nurse P. Life, logic and information. Nature. 2008;454(7203):424-6. PMID:
 460 18650911.
- 461
 461
 462
 462
 463
 463
 463
 463
 463
 463
- Savic S, Caseley EA, McDermott MF. Moving towards a systems-based
 classification of innate immune-mediated diseases. Nat Rev Rheumatol.
 2020;4:222-237.PMID: 32107482.
- Coffey DS. Self-organization, complexity and chaos: The new biology for
 medicine. Nat Med. 1998;8:882-5. PMID: 9701230.
- MacIsaac K, Baumgartner R, Kang J, Loboda A, Peterfy C, DiCarlo J, et al.
 Pre-treatment whole blood gene expression is associated with 14-week
 response assessed by dynamic contrast enhanced magnetic resonance
 imaging in infliximab-treated rheumatoid arthritis patients. PLoS ONE.
 2014;9(12):e111937. PMID: 25504080
- 8. Beals C, Baumgartner R, Peterfy C, Balanescu A, Mirea G, Harabagiu A, et al.
 Magnetic resonance imaging of the hand and wrist in a randomized, doubleblind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis:
 Comparison of dynamic contrast enhanced assessments with semi-quantitative
 scoring. PLoS ONE. 2017;12(12):e0187397. PMID: 29236711
- 479 9. Lequerre T, Gauthier-Jauneau A, Bansard C, Derambure C, Hiron M, Vittecoq
 480 O, et al. Gene profiling in white blood cells predicts infliximab responsiveness in
 481 rheumatoid arthritis. Arth Res Ther. 2006; 8: R105. PMID: 16817978
- 482 10. Julia A, Erra A, Palacio C, Tomas C, Sans X, Barcel P, et al. An eight-gene
 483 blood expression profile. PloS ONE. 2009;4:e7556. PMID: 19847310
- 484
 11. Bienkowska J, Dagin G, Batliwalla F, Allaire N, Roubenoff R, Gregersen PK, et
 485
 486
 486
 487
 487
 487
 488
 489
 480
 480
 480
 480
 481
 481
 482
 483
 484
 485
 485
 485
 486
 486
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
- 12. Toonen EJ, Gilissen C, Franke B, Kievit W, Eijsbouts AM, den Broeder AA, et
 al. Validation study of existing gene expression signatures for anti-TNF
 treatment in patients with rheumatoid arthritis. PLoS ONE. 2012;7(3):e33199.
 PMID: 22457743
- 13. Nakamura S, Suzuki K, lijima H, Hata Y, Lim CR, Ishizawa Y, et al.
 Identification of baseline gene expression signatures predicting therapeutic
 responses to three biologic agents in rheumatoid arthritis: a retrospective
 observational study. Arth Res Ther. 2016;18:159. PMID: 27435242
- 496 14. Tanino M, Matoba R, Nakamura S, Kameda H, Amano K, Okayama T, et al.
 497 Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid
 498 arthritis patients using a comprehensive transcriptome analysis of white blood

499 500		cells. Biochem Biophys Res Commun. 2009 18;387(2):261-5. PMID: 19577537.
501	15.	Ramírez-Mova J. Wert-Lamas L. Acuña-Ruíz A. Fletcher A. Wert-Carvaial C.
502		McCabe CJ, et al. Identification of an interactome network between IncRNAs
503		and miRNAs in thyroid cancer reveals SPTY2D1-AS1 as a new tumor
504		suppressor. Sci Rep. 2022; 12(1):7706. PMID: 35562181
505	16.	Li K. Kong R. Ma L. Cao Y. Li W. Chen R. et al. Identification of potential M2
506 507		macrophage-associated diagnostic biomarkers in coronary artery disease.
507	17	Zhang I, Huang X, Wang X, Gao X, Liu I, Li Z, et al. Identification of notantial
506	17.	crucial gonos in atrial fibrillation: a bioinformatic analysis BMC Mod Conomics
509		2020.13(1).104 PMID: 22682418
510	10	Kim C. Neb III Lee MI. Devic VI. Kim DM. Kim VC at al. Effects of
511	10.	Min 5, Non JR, Lee MJ, Park YJ, Nim BM, Nim YS et al. Effects of
512		Madel Int Mol Sei, 0002:04/00/15206, DMID: 27005006
513	10	Model. Int J Mol Sci. 2023;24(20):15326. PMID: 37895006
514	19.	Zheng C, Yu X, Xu I, Liu Z, Jiang Z, Xu J et al. KC I D4 interacts with CLIC1 to
515		disrupt calcium homeostasis and promote metastasis in esophageal cancer.
516		Acta Pharm Sin B. 2023 13(10):4217-4233. PMID: 37799381
517	20.	Colletti KS, Smallenburg KE, Xu Y, Pari GS. Human cytomegalovirus UL84
518		interacts with an RNA stem-loop sequence found within the RNA/DNA hybrid
519		region of oriLyt. J Virol. 2007; 81:7077-85. PMID: 17459920
520	21.	Davis JM, Knutson KL, Strausbauch MA, Green AB, Crowson CS, Therneau
521		TM et al. Immune response profiling in early rheumatoid arthritis: discovery of a
522		novel interaction of treatment response with viral immunity. Arthritis Res Ther.
523		2013;15(6):R199. PMID: 24267267
524	22.	Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil A,
525		NitithamJ, et al. Rheumatoid arthritis risk allele PTPRC is also associated with
526		response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum.
527		2010;62(7):1849-61. PMID: 20309874
528	23.	Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, et al.
529		Replication of association of the PTPRC gene with response to anti-tumor
530		necrosis factor therapy in a large UK cohort. Arthritis Rheum. 2012;64(3):665-
531		70. PMID: 21952740
532	24.	Poulsen TBG, Damgaard D, Jørgensen MM, Senolt L, Blackburn JM, Nielsen
533		C, et al. Identification of Novel Native Autoantigens in Rheumatoid Arthritis.
534		Biomedicines. 2020;8(6):141. PMID: 32486012
535	25.	Lambert MR, Gussoni E. Tropomyosin 3 (TPM3) function in skeletal muscle
536		and in myopathy. Skelet Muscle. 2023;13(1):18. PMID: 37936227
537	26.	Galea LA, Hildebrand MS, Witkowski T, Joy C, McEvov CR, Hanegbi U, Aga A,
538		ALK-rearranged renal cell carcinoma with TPM3::ALK gene fusion and review
539		of the literature. Virchows Arch. 2023 482(3):625-633. PMID: 36370168
540	27	Ritter SY Subbaiah B Bebek G Crish J Scanzello CB Krastins B et al
541	<u> </u>	Proteomic analysis of synovial fluid from the osteoarthritic knee: comparison
542		with transcriptome analyses of joint tissues. Arthritis Rheum 2013:65(4):981-
543		92. PMID: 23400684
544	28	Lequerré T. Bansard C. Vittecog O. Derambure C. Hiron M. Daveau M. et
545	_0.	al. Early and long-standing rheumatoid arthritis: distinct molecular signatures

546		identified by gene-expression profiling in synovia. Arthritis Res Ther.
547		2009; 11 :R99. PMID: 19563633
548	29.	Badr MT, Häcker G. Gene expression profiling meta-analysis reveals novel
549		gene signatures and pathways shared between tuberculosis and rheumatoid
550		arthritis. PLoS ONE. 2019;14(3):e0213470. PMID: 30845171
551	30.	Mellors T, Withers JB, Ameli A, Jones A, Wang M, Zhang L, et al. Clinical
552		validation of a blood-based predictive test for stratification of response to tumor
553		necrosis factor inhibitor therapies in rheumatoid arthritis patients. Network and
554		Systems Medicine. 2020;3.1:91-104. doi: 10.1089/nsm.2020.0007
555	31.	Jones A, Rapisardo S, Zhang L, Mellors T, Withers JB, Gatalica Z, et al.
556		Analytical and clinical validation of an RNA sequencing-based assay for
557		quantitative, accurate evaluation of a molecular signature response classifier in
558		rheumatoid arthritis. Expert Rev Mol Diagn. 2021;21(11):1235-43. PMID:
559		34727834.
560	32.	Sipper M, Olson RS, Moore JH. Evolutionary computation: the next major
561		transition of artificial intelligence? BioData Min. 2017;10:26. PMID: 28775766
562	33.	Herant M. Working paper: the coming age of algorithmic medicine. In: Recon
563		Strategy 2015 Oct 25 [cited January 21st 2024]. Available
564		from https://reconstrategy.com/2015/10/working-paper-the-coming-age-of-
565		algorithmic-medicine/
566	34.	Obermeyer Z, Emanuel EJ. Predicting the Future - Big Data, Machine Learning,
567		and Clinical Medicine. N Engl J Med. 2016;375(13):1216. PMID: 27682033
568	35.	Schwartz WB. Medicine and the computer - the promise and problems of
569		change. N Engl J Med. 1970;283:1257-64. PMID: 4920342
570	36.	Margolis CZ. Uses of clinical algorithms. JAMA, 1983:249(5):627-32. PMID:
571		6336813
572	37.	Keffer JH. Guidelines and algorithms: perceptions of why and when they are successful
573		and how to improve them. Clin Chem. 2001;47(8):1563-72. PMID: 11468268.
574	38.	Warraich HJ. Califf RM. Krumholz HM. The digital transformation of medicine
575		can revitalize the patient-clinician relationship. NPJ Digit Med. 2018;1:49.
576		PMID: 31304328
577	39.	Raikomar A. Dean J. Kohane I. Machine Learning in Medicine. N Engl J Med.
578		2019:380(14):1347. PMID: 30943338
579	40.	Naughton J. Machine-learning systems are problematic. That's why tech
580		bosses call them 'Al'. The Guardian. 2022 November 5 [Cited January 21st
581		2024]. Available from
582		https://www.theguardian.com/commentisfree/2022/nov/05/machine-learning-
583		systems-are-problematic-thats-why-tech-bosses-call-them-ai
584		
585		
586		

589 Supporting information

590 **S1 File**

- Sheet 1: Data excerpted from GSE58795 on 4 gene expression variables in
- 592 discovery algorithm to enable validation
- Sheet 2: Summary gene expression for all eight variables by treatment group
- Sheets 3-8: x-y plots for DAS28 versus all eight variables by treatment group
- 595 S2 File STARD Diagnostic Checklist





Figure